BiotechTube

Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]

ApprovedTerminated
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy

Trial Timeline

Oct 31, 2020 → May 13, 2021

NCT ID
NCT04708314

About Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]

Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] is a approved stage product being developed by Sarepta Therapeutics for Duchenne Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04708314. Target conditions include Duchenne Muscular Dystrophy.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04708314ApprovedTerminated

Competing Products

20 competing products in Duchenne Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52

Other Products from Sarepta Therapeutics

EteplirsenPhase 3
72
SRP-9005 + CorticosteroidPhase 3
72
Casimersen + GolodirsenPhase 3
72
SRP-9003 + GlucocorticoidPhase 3
72
eteplirsenPhase 3
72